Bristol Myers Squibb (CELG-RI) Net Cash Flow (QoQ) (2009 - 2026)
Bristol Myers Squibb (CELG-RI) Net Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.97% |
| Mar 31, 2026 | 89.35% |
| Dec 31, 2025 | -276.76% |
| Sep 30, 2025 | 93.97% |
| Jun 30, 2025 | 248.05% |
| Mar 31, 2025 | -82.24% |
| Dec 31, 2024 | 71.12% |
| Sep 30, 2024 | 150.40% |
| Jun 30, 2024 | -40.93% |
| Mar 31, 2024 | -155.25% |
| Dec 31, 2023 | 572.89% |
| Sep 30, 2023 | -33.17% |
| Jun 30, 2023 | -112.07% |
| Mar 31, 2023 | -122.78% |
| Dec 31, 2022 | 143.34% |
| Sep 30, 2022 | -89.73% |
| Jun 30, 2022 | 11.34% |
| Mar 31, 2022 | -455.60% |
| Dec 31, 2021 | -80.44% |
| Sep 30, 2021 | 4,227.59% |